2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Drug Development, Biological Processes, Molecular Biology, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Infectious Diseases, Research, Fundamental Science, Translational Research, Study Population, Animal Model
PAPER

1270 Beyond blood loss: Clot ultrastructure reveals treatment-dependent differences in hemophilia B mice

Sebastian E. Leyes Porello, B.S. Biochemistry, Irina Chernysh2, Julia Q. Chau3, Kyumin Lee4, John Weisel, PhD5, Ben Samelson Samelson-Jones, MD PhD6
1 The Children's Hospital of Philadelphia, Philadelphia, United States
2 University of Pennsylvania, Philadelphia, United States
3 The Children's Hospital of Philadelphia, Philadelphia, United States
4 The Children's Hospital of Philadelphia, Philadelphia, United States
5 University of Pennsylvania, Philadelphia, United States
6 The Children's Hospital of Philadelphia, Philadelphia, United States

Introduction: Factor (F)VIIIa-mimetics such as emicizumab have transformed the treatment of hemophilia A (HA). Emerging preclinical studies suggest that FVIIIa-mimetics can be repurposed for select genotypes of hemophilia B (HB) with impaired FVIIIa/FIXa complex formation, including FIX-R333Q (Lee et al. Blood. 2024). Previous studies in HA mice demonstrated ultrastructural differences between clots formed after treatment with FVIII versus emicizumab (Sefiane et al. Haematologica. 2024). Specifically, emicizumab-generated clots contained patches of fused fibrin fibers with fewer entrapped red blood cells (RBCs), whereas FVIII-generated clots exhibited a more uniform fibrin meshwork. Here, we investigated whether ultrastructural differences occur in HB mice treated with FIX or a FVIIIa-mimetic.    

Methods: Clots formed in treated HB mice after tail-vein transection (TVT) were collected and visualized using scanning electron microscopy. In this model, untreated HB mice exhibit greater blood loss and longer bleeding times compared to wild-type mice (33 versus 3 µL/g and 31 versus 6 min, respectively).

Results: HB mice received one of four different hemostatic treatments prior to TVT (n=3 per cohort): (A) 1 mg/kg commercial recombinant wild-type FIX (rFIX-WT); (B) 2 mg/kg rFIX-WT; (C) 1 mg/kg rFIX-WT + 1.5 mg/kg FX; and (D) 1.5 mg/kg rFIX-R333Q + 1 mg/kg Mim8 + 1.5 mg/kg FX. All four treatments normalized hemostasis with similar total blood loss and bleeding times (mean ± SD): 3.8 ± 0.9 µL/g and 5.2 ± 1.0 min for cohort A; 2.7 ± 0.4 µL/g and 5.2 ± 0.4 min for cohort B; 2.8 ± 0.2 µL/g and 5.4 ± 0.2 min for cohort C; and 5.7 ± 2.5 µL/g and 5.3 ± 0.4 min for cohort D.

Despite similar hemostatic outcomes, clot ultrastructure differed markedly among treatments. The external surface of clots from cohort A consisted of a sparse fibrin network ensnaring tightly packed but predominantly biconcave RBCs. In contrast, the external surface of clots from cohorts B, C, and D displayed a dense, multilayered fibrin meshwork. RBCs were less readily visualized because of the density of the fibrin meshwork but were variable in shape. No qualitative differences in ultrastructure were observed among cohorts B, C, and D. Fibrin fiber diameter and branching appeared similar across all cohorts, although cohort A contained substantially fewer fibers. The interiors of clots from cohorts B, C, and D were densely packed with pleiomorphic RBCs, including polyhedrocytes. The interiors of cohort A clots could not be examined because of their fragility. Quantitative image analysis is ongoing.

 Conclusions: Hemostatic clots from treated HB mice exhibit distinct ultrastructural differences despite comparable blood loss and bleeding times. Treatment with only 1 mg/kg rFIX-WT alone produced a sparse fibrin network with less RBC deformation. Doubling the rFIX-WT dose or supplementing the 1 mg/kg rFIX-WT with FX generated a dense fibrin network. FVIIIa-mimetic treatment with FIX-R333Q also produced hemostatic clots with a dense fibrin network qualitative and ultrastructural features comparable the higher dose of rFIX-WT or FX augmentation. These findings support the in vivo hemostatic activity of FVIIIa-mimetics in select genotypes of HB. They further suggest that bleeding parameters may be relatively insensitive to differences in clot quality and microstructure.

Sebastian E. Leyes Porello, B.S. Biochemistry: No relevant conflicts of interest to declare.